Early clearance for R-B, Adams
This article was originally published in The Tan Sheet
Slough, U.K.-based Reckitt Benckiser on Jan. 8 announced the receipt of an early termination of the waiting period under the Hart-Scott-Rodino Act regarding its offer to purchase all outstanding shares of Adams Respiratory Therapeutics' stock. Through its wholly owned subsidiary Twickenham, Reckitt, a household cleaning, health and personal care product firm, made an offer in December to purchase all Chester, N.J.-based Adams' outstanding stock for $60 per share (1"The Tan Sheet" Dec. 17, 2007, p. 5)...
You may also be interested in...
Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.